Previous 10 | Next 10 |
Merger activity increased last week with one new deal announced. The acquisition of Standard AVB Financial by Dollar Mutual Bancorp. InnerWorkings receives shareholder approval. For further details see: Merger Arbitrage Mondays - A Very Active Quarter Draws To A Clo...
WeissLaw LLP Reminds MR, IMMU, and BMCH Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, Sept. 25, 2020 NEW YORK , Sept. 25, 2020 /PRNewswire/ -- Montage Resources Corporation WeissLaw LLP is investigating possible b...
The healthcare sector has been led by the biotech and pharmaceutical industries. These industries have led the fight against COVID and cancer. Here are four biotech stocks that should continue to benefit from current trends: Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Genmab A/S (GMAB) and,...
Over the weekend, Immunomedics (NASDAQ: IMMU) presented previously undisclosed clinical trial results for Trodelvy, a recently approved cancer drug. Gilead Sciences (NASDAQ: GILD) turned a lot of heads when it offered a 108% premium in its buyout bid for Immunomedics ear...
Immunomedics (IMMU) announced positive results from cohort 1 (n=113) of cisplatin-eligible patients in Phase 2 TROPHY U-01 study of Trodelvy (sacituzumab govitecan-hziy) in metastatic urothelial cancer (mUC).Results confirmed the interim findings and prior Phase 1/2 study results showing Trod...
Immunomedics (IMMU) announces results from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) compared to treatment of choice ((TPC)) standard single-agent chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC) who had previously received at least t...
Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC) sBLA submission for accelerated approval expected in fourth quarter 2020, pending FDA final guidance Phase 3 TROPi...
Trodelvy significantly red uced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard single-agent chemothera py Trodelvy is the first ADC to signif icant ly improve OS in metasta...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Stocks sank to six-week lows in a bout of broad selling, with the S&P 500 slipping more than 1% for its third straight decline and a...
Dozens of healthcare stocks grew by double-digit percentages last week, and shares of these three drugmakers rose further than nearly all of their peers. Clinical trial results, coronavirus vaccine progress, and a buyout were the major factors that turned these biotech stocks into big gainers la...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences (NASDAQ: GILD) can be both a hero and a goat, depending on your perspective as an investor. The stock price rose from $17 in July 2010 to $118 in July 2015, as the company introduced revolutionary HIV drugs and helped bring a cure for hepatitis C to market. Since the...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products...